Rui Huang1, Huiying Rao1, Ming Yang1,2, Yinghui Gao1, Jian Wang1, Qian Jin1, Danli Ma1, Lai Wei3,4. 1. Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, No. 11 Xizhimen South Street, Beijing, 100044, China. 2. Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China. 3. Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, No. 11 Xizhimen South Street, Beijing, 100044, China. weelai@163.com. 4. Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China. weelai@163.com.
Abstract
BACKGROUND: Short-time usage of direct-acting antiviral agents (DAA) limited knowledge regarding histological outcomes and predictive values of noninvasive measurements in patients with hepatitis C virus (HCV) after sustained virologic response (SVR) with DAA. AIMS: This study aimed to indicate histological changes and assess predictive value of noninvasive measurements for fibrosis in these patients. METHODS: HCV patients who achieved SVR by DAA were identified. Pre- and post-SVR clinical and histological data were collected. RESULTS: Of patients, 83% (33/40), 38% (15/40) and 83% (33/40) achieved inflammation improvement, fibrosis regression and histological improvement, respectively. Liver stiffness measurements (LSM), APRI, and FIB-4 could predict post-SVR fibrosis well without significant differences. Areas under receiver operating characteristic curves of LSM, APRI, and FIB-4 were 0.78, 0.81, and 0.87 for post-SVR advanced fibrosis (≥ F4) and 0.86, 0.86, and 0.85 for post-SVR cirrhosis (≥ F5), respectively. Pre-SVR LSM, APRI, and FIB-4 values were significantly lower in patients with fibrosis regression (P = 0.003-0.012), while FIB-4 was significantly lower in patients with histological improvement (P = 0.012-0.033). Patients with higher pre-SVR Ishak scores tended to have bigger decline in APRI (P = 0.025) and FIB-4 (P = 0.024) after SVR. CONCLUSIONS: DAA could improve liver inflammation and fibrosis of HCV patients in a short time after SVR. LSM, APRI, and FIB-4 predict fibrosis well even after SVR by DAA. Most of the cutoff values for advanced fibrosis (≥ F4) and cirrhosis (≥ F5) of these noninvasive measurements decreased significantly after SVR, maybe because of the inflammation improvement.
BACKGROUND: Short-time usage of direct-acting antiviral agents (DAA) limited knowledge regarding histological outcomes and predictive values of noninvasive measurements in patients with hepatitis C virus (HCV) after sustained virologic response (SVR) with DAA. AIMS: This study aimed to indicate histological changes and assess predictive value of noninvasive measurements for fibrosis in these patients. METHODS:HCVpatients who achieved SVR by DAA were identified. Pre- and post-SVR clinical and histological data were collected. RESULTS: Of patients, 83% (33/40), 38% (15/40) and 83% (33/40) achieved inflammation improvement, fibrosis regression and histological improvement, respectively. Liver stiffness measurements (LSM), APRI, and FIB-4 could predict post-SVR fibrosis well without significant differences. Areas under receiver operating characteristic curves of LSM, APRI, and FIB-4 were 0.78, 0.81, and 0.87 for post-SVR advanced fibrosis (≥ F4) and 0.86, 0.86, and 0.85 for post-SVR cirrhosis (≥ F5), respectively. Pre-SVR LSM, APRI, and FIB-4 values were significantly lower in patients with fibrosis regression (P = 0.003-0.012), while FIB-4 was significantly lower in patients with histological improvement (P = 0.012-0.033). Patients with higher pre-SVR Ishak scores tended to have bigger decline in APRI (P = 0.025) and FIB-4 (P = 0.024) after SVR. CONCLUSIONS:DAA could improve liver inflammation and fibrosis of HCVpatients in a short time after SVR. LSM, APRI, and FIB-4 predict fibrosis well even after SVR by DAA. Most of the cutoff values for advanced fibrosis (≥ F4) and cirrhosis (≥ F5) of these noninvasive measurements decreased significantly after SVR, maybe because of the inflammation improvement.
Entities:
Keywords:
Aspartate aminotransferase-to-platelet ratio index (APRI); Direct-acting antiviral agents (DAA); Fibrosis-4 (FIB-4); Hepatitis C virus (HCV); Histological improvement; Liver stiffness measurement (LSM)
Authors: B Coco; F Oliveri; A M Maina; P Ciccorossi; R Sacco; P Colombatto; F Bonino; M R Brunetto Journal: J Viral Hepat Date: 2007-05 Impact factor: 3.728
Authors: V Knop; D Hoppe; T Welzel; J Vermehren; E Herrmann; A Vermehren; M Friedrich-Rust; C Sarrazin; S Zeuzem; M-W Welker Journal: J Viral Hepat Date: 2016-08-08 Impact factor: 3.728
Authors: Khalid Alswat; Fahad Al-Sohaibani; Abdullah Khathlan; Ahmad Bashmail; Mohammed Alanazi; Amr Kurdi; Abdul Hakim Almakadma; Waleed Al-Hamoudi Journal: Ann Saudi Med Date: 2022-04-07 Impact factor: 1.526
Authors: Mohammad Said Ramadan; Filomena Boccia; Simona Maria Moretto; Fabrizio De Gregorio; Massimo Gagliardi; Domenico Iossa; Emanuele Durante-Mangoni; Rosa Zampino Journal: J Clin Med Date: 2022-09-29 Impact factor: 4.964